Novel plant-derived target drugs: A step forward from licorice?

Research output: Contribution to journalArticlepeer-review


Isoliquiritigenin (ISL) is a chalcone compound with valuable pharmacological properties such as antioxidant, anti-inflammatory, anticancer and anti-allergic activities. With regard to anticancer property, ISL was able to suppress HIF-1α level, VEGF expression and secretion, cell migration and to decrease the expression and secretion of MMP-9/-2. These effects may be mediated through inhibition of p38, PI3K/Akt and NF-κB signaling pathways. Thus, low concentration of ISL may have therapeutic potential in the treatment of aggressive breast carcinoma and other neoplasms.

Original languageEnglish
Pages (from-to)333-335
Number of pages3
JournalExpert Opinion on Therapeutic Targets
Issue number4
Publication statusPublished - Apr 2013


  • Breast cancer
  • Chalcone
  • Isoliquritrigenin
  • MCF-7

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Novel plant-derived target drugs: A step forward from licorice?'. Together they form a unique fingerprint.

Cite this